Revisiting the public health implications of the United States–Mexico– Canada agreement
Research output: Journal Publications and Reviews (RGC: 21, 22, 62) › Letter › peer-review
Author(s)
Related Research Unit(s)
Detail(s)
| Original language | English |
|---|---|
| Article number | 50 |
| Number of pages | 2 |
| Journal / Publication | Globalization and Health |
| Volume | 16 |
| Online published | 5 Jun 2020 |
| Publication status | Published - 2020 |
Link(s)
| DOI | DOI |
|---|---|
| Attachment(s) | Documents
Publisher's Copyright Statement
|
| Link to Scopus | https://www.scopus.com/record/display.uri?eid=2-s2.0-85086008430&origin=recordpage |
| Permanent Link | https://scholars.cityu.edu.hk/en/publications/publication(5bb2f920-51a4-4efc-b513-cce9825c5387).html |
Abstract
This commentary re-examines a recent article by Labonté et al on the recent changes to two relevant provisions relating to patent rights in the final version of the United-States-Mexico-Canada Agreement (USMCA). Although the USMCA’s final revised version does not add more pharmaceutical patent protection than those that already exist in the three trading partners, the agreement has done little to enhance access to generic medicines and biosimilars.
Research Area(s)
- Public health, USMCA, Pharmaceutical patent, Biologics
Citation Format(s)
Revisiting the public health implications of the United States–Mexico– Canada agreement. / Adekola, Tolulope Anthony.
In: Globalization and Health, Vol. 16, 50, 2020.Research output: Journal Publications and Reviews (RGC: 21, 22, 62) › Letter › peer-review
Download Statistics
No data available
